Followers | 21 |
Posts | 2457 |
Boards Moderated | 1 |
Alias Born | 09/01/2009 |
Saturday, May 07, 2011 1:48:23 PM
It's not that I don't recognize it takes no guts to point out bearish stocks on a bearish day like today. Let's face it through - some stocks are a lot more vulnerable than others. Here's a look at three from that 'highly vulnerable' group that may have started serious downside moves on Wednesday.
In an ironic twist, small cap stock Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) is becoming a victim of its own success. Gaining more than 300% since June of last year, this pharma name has been over-extended for months; the 100% separation between it and its 200-day moving average line is almost unheard of.
Of course, the price is being paid now, and things are apt to get worse for JAZZ before they get better. Thanks to today's 7.6% dip (so far), the stock's now under its 50-day moving average line for the first time in many, many months. That alone is a big sell signal, and when all those previous buyer start seeing their profits threatened, Jazz Pharmaceuticals will likely see a nasty wave of profit-taking.
http://www.smallcapnetwork.com/Uh-Oh-More-Than-Just-a-Little-Trouble-for-DRYS-KRO-and-JAZZ/s/article/view/p/mid/1/id/1794/
Recent JAZZ News
- Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer • PR Newswire (US) • 07/09/2024 11:45:00 AM
- Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer • PR Newswire (US) • 07/09/2024 11:45:00 AM
- Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor • PR Newswire (US) • 06/20/2024 11:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/14/2024 08:12:50 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/14/2024 08:11:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 12:15:22 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 08:44:32 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/03/2024 08:28:09 PM
- Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 • PR Newswire (US) • 06/01/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 09:01:02 PM
- Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 • PR Newswire (US) • 05/30/2024 11:30:00 AM
- Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences • PR Newswire (US) • 05/29/2024 08:15:00 PM
- Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences • PR Newswire (US) • 05/29/2024 08:15:00 PM
- Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer • PR Newswire (US) • 05/29/2024 11:45:00 AM
- Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism • PR Newswire (US) • 05/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:31:10 PM
- Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference • PR Newswire (US) • 05/01/2024 08:10:00 PM
- Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference • PR Newswire (US) • 05/01/2024 08:10:00 PM
- Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance • PR Newswire (US) • 05/01/2024 08:05:00 PM
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 • PR Newswire (US) • 04/24/2024 08:05:00 PM
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 • PR Newswire (US) • 04/17/2024 08:15:00 PM
- Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting • PR Newswire (US) • 04/10/2024 11:45:00 AM
- Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer • PR Newswire (US) • 04/02/2024 11:30:00 AM
- Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 • PR Newswire (US) • 03/12/2024 08:15:00 PM
- Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 • PR Newswire (US) • 03/12/2024 08:15:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM